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OBJECTIVE
Assess the accuracy of the nuchal translucency (NT) 
measurement between 11 and 13 weeks and 6 days of 
gestation as a sonographic marker to screen for congenital 
heart defects (CHD).
METHODS
This is a multi-center retrospective study in which 
singleton gestations of euploid fetuses were analyzed. 
NT measurement was performed in the first trimester 
examination when the fetal crown-rump length (CRL) was 
45 to 84 mm, according to the criteria established by the 
Fetal Medicine Foundation. The cases were followed up to 
one month postpartum to assess the presence of CHD.
RESULTS
Three thousand six hundred and sixty four gestations 
were analyzed, of which twenty newborn infants had 
some congenital heart defect up to the first month of life 
(prevalence of 0.55%). The median NT in fetuses with 
CHD was 1.70 mm, and 1.60 mm in fetuses without 
CHD. However no statistically significant difference was 
observed between the two medians (Mann-Whitney test, 
p > 0.05). The NT sensitivity to detect CHD ranged from 
15% to 20%, with a probability of false positive cases of 
86.4% to 97.9%, depending on the cut-off point used. 
Odds ratio for CHD was high when compared to the 
classical indications for fetal echocardiography, ranging 
from 4.7 to 33.7, according to the cut-off point used.
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CONCLUSION
Despite the low sensitivity of the test, increased NT is 
an important risk factor for CHD, and should be included 
in the strategy of prenatal screening for these diseases.
KEY WORDS
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Congenital heart defects (CHD) comprise an important 
part of all major congenital malformations which affect 
2% to 3% of newborn infants (NBI)1. The prevalence of 
CHD in the general population is estimated at 8:1000 
live births2. When fetal deaths are studied, the incidence 
of CHD ranges from 0.5% to 39.5%, according to the 
gestational age at which the fetal loss occurred. The 
earliest deaths are mainly associated with the presence 
of complex CHDs3.  An average of 35% of child deaths 
are related to CHD4; therefore, CHDs are an important 
issue in the context of neonatal and child death. 
Starting from the principle that the earlier the 
diagnosis of CHD is made the better the prognosis5,
some authors have studied the impact of the utilization 
of fetal echocardiography on the reduction of neonatal 
morbidity and mortality. Encouraging results are observed 
especially in the following CHDs: (1) hypoplastic left heart 
syndrome6,7; (e) transposition of the great arteries8; and 
(3) coarctation of the aorta9.
Unfortunately, the detection of CHD in the prenatal 
period is low because the ultrasound specialist that 
performs the obstetric examination is not trained for 
a correct assessment of the anatomy of the heart. 
Population-based studies on the performance of routine 
examinations demonstrate disappointing detection rates 
ranging from 6% to 35%10. In addition, the request of 
a specialized fetal echocardiography examination based 
on risk factors does not provide the detection of most of 
the CHDs11.
Nuchal translucency (NT) is the hypoechogenic space 
between the skin and the subcutaneous tissue that covers 
the cervical spine of the fetus. Since the beginning of 
the 1990’s several studies with small case series and 
high risk populations have demonstrated the association 
of increased NT thickness measured between eleven 
weeks of gestation and thirteen weeks and six days of 
gestation with the presence of chromosomal anomalies12.
The pathophysiological mechanisms that explain this 
transient sonographic marker are not well established 
yet13. Some events that occur in this phase of pregnancy 
could occasionally explain the transient accumulation 
of liquid in the fetal nuchal region, which is attributed 
to alterations in the fetal lymphatic drainage and/or, 
particularly, to fetal hemodynamic disorders related to 
heart failure14-16.
It would be very useful to find a marker such as the 
NT, able to screen which patients among the low risk 
population should undergo fetal echocardiography. In 
view of the use of an increased NT as an indication for 
fetal echocardiography, the objective of this study was to 
evaluate the accuracy of NT in the screening of CHD. 
METHODS
A multi-center retrospective study for validation of a 
diagnostic test was conducted. Two study centers were 
included: the first one in Florianópolis (State of Santa 
Catarina, Brazil), and the second one in Vitória (State 
of Espírito Santo, Brazil). The pregnant women included 
in the study underwent ultrasonographic examination at 
these centers to measure NT between eleven weeks and 
thirteen weeks and six days of gestation, as estimated by 
the crown-rump length (from 45 to 84 mm). The following 
inclusion criteria were used: (1) singleton gestations; (2) 
normal fetal karyotype and/or normal phenotype.
Fetal heart assessment was performed with a neonatal 
clinical examination or, when necessary, with fetal and/or 
neonatal echocardiography. All cases were followed up 
until at least one month after delivery. Relevant data 
were obtained from the database kept by the institutions 
participating in the study or through contact with the 
patient’s physician.
The equipment used to perform the examinations 
were: Acuson™ XP10, Acuson™ Aspen™, Medison™ 
SONOACE™ 9900, Toshiba™ SSH-140A and GE™ 
Voluson 730. The examinations were performed by doctors 
from each center’s medical staff, using the technique 
recommended by the Fetal Medicine Foundation (FMF): 
(1) the image should be obtained from a sagittal section 
of the fetus with a magnification large enough for the 
cephalic pole to occupy 75% of the image; (2) fetal head 
should be in a neutral position in relation to the body; (3) 
care should be taken to distinguish fetal skin and amnion; 
(4) the widest part of translucency is measured.
After data collection a descriptive univariate analysis of 
the variables of interest was performed. The Kolmogorov-
Smirnov test was used to verify whether NT values 
distribution was normal.
In the variables with a normal distribution the mean 
was used to represent the measurement of the central 
trend of the sample. In the same cases, the standard 
deviation was calculated to measure the sample 
dispersion, and the Student’s t parametric test was used 
to verify the occurrence of statistical significance.
In the variables with a non-normal distribution we 
chose to use a non-parametric test to evaluate the 
statistical significance. The Mann-Whitney test was used 
in such cases. Since in non-normal distributions the mean 
is under a great influence of the extreme values of the 
distribution (also known as outliers), we chose the median 
to represent the central measurement of the sample, and 
the dispersion was represented as percentiles. P values 
< 0.05 were considered significant. 
The database was then divided into two groups, the 
first of which was named non-CHD group, and the second 
was named CHD group. Using the non-CHD group, the 
1st, 5th, 10th, 25th, 50th, 75th, 90th, 95th, and 99th 
percentiles of the absolute value of NT were determined 
in millimeters for the whole sample of normal cases. 
These percentiles were also determined in relative values 
expressed as multiples of the median, considering that the 
median NT value varies according to the CRL. Further, 
sensitivity, specificity, positive and negative predictive 
values, and the probability of false positives and false 
negatives were calculated.
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The present study was analyzed and approved by the 
Research Ethics Committee of the Universidade Federal 
de São Paulo in July, 2nd, 2004, process number 
0665/04.
RESULTS
The final sample of the study comprised 3,664 
examinations. The number of examinations performed 
at each center was relatively similar: 56% (2,061) of 
them were performed in Vitória and 44% (1,603) in 
Florianópolis.
Patients’ ages ranged from fourteen to 53 years, with 
a mean of 32 years. The mean age was higher in the 
group of patients from Florianópolis than in the group from 
Vitória, and was 34.5 years and 30.2 years, respectively 
(Tab. 1). 
Twenty cases of congenital heart defect were 
diagnosed in the sample studied. Of these, fifteen were 
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diagnosed at Florianópolis Center and five at Vitória 
Center, representing a prevalence of 0.94% and 0.24%, 
respectively. The cases of heart defects diagnosed are 
described in Table 2.
The following alterations were observed during the 
morphologic obstetric examination performed at the 
Florianópolis Center: one case with sinusal bradycardia, 
two cases with supraventricular tachycardia and three 
cases of premature atrial contractions. These cases were 
not included as CHD because they were primarily related 
to disorders of the heart rhythm. 
A progressive increase in the prevalence of CHD 
according to the NT values obtained in the examination 
was observed, as shown in Table 3.
NT value distribution in the cases without CHD was 
not normal, as identified by the Kolmogorov-Smirvov test, 
in which the p value calculated was lower than 0.05. To 
demonstrate that the NT value distribution did not follow 
Table 1 - Mean maternal age according to the center where the examination was performed
n Mean SD Minimum Maximum
Florianópolis 1,603 34.5 5.6 17 53
Vitória 2,061 30.2 5.3 14 49
Total 3,664 32.0 5.9 14 53
(t test, p < 0.05) SD = Standard deviation.
Table 2- Cases of congenital heart defects diagnosed in the sample
Case Age Center GA CRL NT Median NT MoM CHD
1 35 Florianópolis 13 71 1.5 1.77 0.84 Moderate pulmonary stenosis 
2 41 Florianópolis 11 53 1.9 1.41 1.34 Severe pulmonary stenosis
3 41 Florianópolis 12 62 1.7 1.60 1.06 Pulmonary atresia, RV hypoplasia, VSD
4 38 Florianópolis 11 57 1.5 1.49 1.00 Pulmonary atresia, Tricuspid regurgitation, RV hypoplasia
5 45 Florianópolis 12 58 1.3 1.51 0.85 VSD
6 39 Florianópolis 13 77 2.3 1.87 1.22 Severe tricuspid regurgitation
7 36 Florianópolis 12 53 1.9 1.41 1.34 Aortopulmonary window
8 23 Florianópolis 13 80 1.4 1.92 0.72 VSD
9 31 Florianópolis 13 78 1.7 1.89 0.89 VSD
10 41 Florianópolis 14 79 2 1.91 1.04 VSD and ASD
11 33 Florianópolis 13 73 21 1.81 11.59
Cervical cystic hygroma, VSD, pericardial effusion, pleural 
effusion, ascitis, hydrops
12 41 Florianópolis 12 61 1.7 1.58 1.07 Ductus arteriosus aneurysm
13 23 Florianópolis 13 62 1 1.60 0.62 VSD, single umbilical artery, esophageal atresia
14 28 Florianópolis 11 50 1.1 1.34 0.81 VSD
15 32 Florianópolis 12 56 0.9 1.47 0.61 Bilateral choroid plexus cyst, VSD
16 30 Vitória 13 79.2 1.6 1.91 0.83 VSD
17 25 Vitória ? 65 2 1.66 1.20 Severe pulmonary stenosis
18 36 Vitória 13 75 4 1.84 2.16
Atrioventricular septal defect Total atrioventricular septal 
defect
19 29 Vitória 11 45 5 1.24 4.02 Ostium Primum ASD
20 23 Vitória 13 73 14 1.81 7.72 Complex cardiac malformation
GA - gestational age estimated by the last menstrual period; CRL - crown-rump length measured on the day of examination; NT - nuchal 
translucency measurement; Median NT - median nuchal translucency calculated according to the CRL; MoM - nuchal translucency measured 
in multiples of the median for the respective CRL; ? - last menstrual period is unknown; VSD - ventricular septal defect; ASD - atrial septal 
defect; RV - right ventricle.
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a normal curve, we created the normal quantile-quantile 
plot of NT values (Figure 1).
Median NT was 1.70 mm for the cases with CHD, and 
1.60 for the non-CHD group; however, this difference was 
not statistically significant, as shown in Table 4.
Among the non-CHD cases, the percentile values found 
for NT were as follows (Tab. 5):
Different cut-off points were used to evaluate the 
accuracy of NT in the screening of CHD. These values 
can be observed in Table 6.
Fig. 2 shows normal and abnormal case distribution 
plot in relation to CRL and NT measurement, marking 
the several cut-off points studied.
The odds ratio of the presence of CHD according to 
the NT thickness was also determined (Tab. 7). 
The number needed to screen (NNS) was calculated 
to illustrate the efficacy of the method. The NNS is a 
new statistical method that has gained attention as a 
form of reporting results of dichotomous tests17. The 
NNS is defined as the number of patients that need to 
be screened, in average, to achieve some benefit (in this 
case, the number of patients undergoing echocardiography 
to diagnose one CHD) (Tab. 8). 
Fig. 1 – Normal quantile-quantile plot of NT values.
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Table 4 - Absolute NT values according to the presence of CHD
n Median (mm) Minimum (mm) Maximum (mm)
With CC 20 1.70 0.9 21
Without CC 3,644 1.50 0.5 13
Total 3,664 1.60 0.5 21
(Mann-Whitney test, p > 0.05).
Table 3 – Prevalence of CHD according to the NT values obtained
NT total n n of CHD
Prevalence
(per 1,000 fetuses)
Up to 2.5 mm 3,506 16 4.5
2.6 to 3.5 mm 127 0 0
3.6 to 4.5 mm 16 1 62.5
4.6 to 5.5 mm 6 1 166.7
Above 5.6 mm 9 2 222.2
Total 3,664 20 5.6

Arquivos Brasileiros de Cardiologia - Volume 87, Nº 3, September 2006
Bruns et al
THE ROLE OF NUCHAL TRANSLUCENCY IN THE SCREENING OF CONGENITAL HEART DEFECTS
Table 5 – NT percentiles in absolute values (millimeters) and relative values (MoM, multiples of the median)
Percentile NT (mm) NT (MoM)
1 0.74 0.50
5 0.90 0.63
10 1.00 0.70
25 1.30 0.83
50 1.60 1.00
75 1.90 1.19
90 2.30 1.37
95 2.50 1.51
99 3.16 2.04
Table 6 – Values found for sensitivity (S), specificity (E), positive predictive value (PPV), negative predictive 
value (NPV), probability of false positive (PFP), and probability of false negative (PFN)
Cut-off point S E PPV NPV PFP PFN
2.5 mm 20.0 % 95.8 % 2.5 % 99.5 % 97.5 % 0.5 %
3.5 mm 20.0 % 99.3 % 12.9 % 99.6 % 87.1 % 0.4 %
4.0 mm 15.0 % 99.5 % 13.6 % 99.5 % 86.4 % 0.5 %
95th Percentile 20.0 % 95.0 % 2.1 % 99.5 % 97.9 % 0.5 %
95th Percentile 20.0 % 99.0 % 10.0 % 99.6 % 90.0 % 0.4 %
Fig. 2 – Correlation between the nuchal translucency measurement and CRL in the non-CHD (n = 3644) and CHD (n = 20) groups. The solid black 
lines depict the 5th, 50th, and 95th percentiles, whereas the red dotted lines depict the 2.5, 3.5, and 4.5-mm cut-off points.
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Table 7 – Odds ratio (OR) and 95% confidence 
interval (95% CI) according to the different cut-off 
points
Cut-off points OR 95% CI p
> 2,5 mm 5.8 1.4 - 17.8 < 0.05
> 3,5 mm 33.5 7.6 - 112.8 < 0.05
> 4,0 mm 33.7 5.8 - 130.6 < 0.05
> 95th percentile 4.7 1.1 - 14.8 < 0.05
> 95th percentile 25.0 5.8 - 82.6 < 0.05
Table 8 – Number needed to screen (NNS) and 
95% confidence interval (95% CI) according to the 
different cut-off points 
Cut-off point NNS 95% CI
> 2.5 mm 48 21 - 200
> 3.5 mm 8 4 - 21
> 4.0 mm 8 3 - 23
> 95th percentile 60 25 - 297
> 95th percentile 10 5 - 28276
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DISCUSSION
Much has been discussed recently about the 
importance of the prenatal diagnosis of congenital 
malformations. With the improvement in the quality of 
ultrasound equipment in the past two decades and with 
the training of professionals capable of performing fetal 
morphologic analysis, the sensitivity of the examination 
has reached values close to 83%18. Prenatal diagnosis of 
fetal diseases enables actions aimed at the maternal and 
fetal well-being, thus greatly improving the prognosis of 
the newborn infant. 
Despite the advances in the detection of fetal 
malformations, however, the detection of CHD is far from 
being optimal. The difficulty to obtain images with the 
organ in movement and the vast anatomic knowledge 
required are pointed as the major factors that make CHD 
a difficult diagnosis19. Therefore, the analysis of the fetal 
heart depends a great deal on the examiner’s experience, 
and the sensitivity of the ultrasound examination for the 
detection of CHD may range from 40% to 90%, even 
when performed by echocardiography specialists20.
NT is recognized as a marker for risk assessment of 
chromosome diseases. Although the pathophysiology of 
the increased NT in fetuses with chromosome diseases is 
not fully understood, this correlation is well established. 
Several pathophysiologic mechanisms have been implied 
in the increased NT, including heart failure. 
Heart failure in adults is known to produce edema of 
the lower extremities, particularly due to the gravitational 
action, and this edema is more pronounced by the end of 
the day. Increased NT was associated with the increase in 
the gene expression of heart failure markers21. However, 
how fetal heart failure could cause edema restricted to 
the nuchal region remains unknown. 
NT measurement is a simple method to be learned and 
is easily reproducible. The demonstration of a correlation 
between increased NT and CHD would be extremely 
interesting from an epidemiological point of view for the 
screening of CHD, and this was our major motivation to 
carry out this study. 
In our sample, the use of NT as a screening method for 
CHD showed a low sensitivity – of 20% when the 95th 
percentile was used as the cut-off point.  However, the 
specificity of the method was high: 99.4% for the 4.0 mm 
cut-off point. The negative predictive value was always 
above 99% at the different cut-off points. The association 
between any form of CHD (isolated or a group that could 
induce a similar hemodynamic alteration) and increased 
NT could not be determined.
The very high specificity and negative predictive values 
qualify the examination as an important tool to reassure 
parents, because the likelihood of heart disease in the 
presence of a normal NT is very low – less than 1%.
CHDs, in turn, are uncommon among the low risk 
population, with an incidence lower than 1%. Performing 
a screening test to conclude that the risk after the test (a
posteriori risk) is equal to the risk prior to the test (a priori
risk) does not show any benefit from its use. 
Thus, the test would likely have a greater impact for 
groups at high risk for CHD, such as mothers who already 
had a child with CHD, whose recurrence risk is of 2%-
3% in subsequent gestations22, or for mothers with CHD, 
whose recurrence risk may reach 5%-10%23. In cases in 
which the CHD is part of a genetic syndrome, the risk of 
recurrence is equivalent to that attributed to the risk of 
recurrence of the genetic disease. In these groups, an a
posterior risk lower than 1% would be very reassuring. 
However, it would not exclude the need for a thorough 
assessment using fetal echocardiography.
Although the 20% sensitivity found in our sample is not 
as encouraging as the best results already published, it is 
in agreement with the values available in the literature, 
that range from 11.1% to 56%. In a meta-analysis 
published by Makrydimas et al24, the estimated sensitivity 
of NT in the screening of CHD was 37%. This large 
Table 9 – Comparison between odds ratio (OR) and 95% confidence interval (95% CI) values found with other 
risk factors for CHD 
Risk Factor
Consanguineous parents 1.2 1.1 - 1.3 NS
Extracardiac malformation 31.1 15.1 - 60.9 < 0.05
Chromosome anomaly 34.5 23.3 - 49.8 < 0.05
Maternal exposure to teratogenic agents 0.9 0.5 - 1.6 NS
Prior child with congenital heart defect 12.4 10.3 - 14.4 < 0.05
Mother with congenital heart defect 2.3 1.1 - 1.7 < 0.05
Father with congenital heart defect 1.3 0.5 - 4.3 NS
NT > 2.5 mm 5.8 1.4 - 17.8 < 0.05
NT > 3.5 mm 33.5 7.6 - 112.8 < 0.05
NT > 4.0 mm 33.7 5.8 - 130.6 < 0.05
NT > 95th percentile 4.7 1.1 - 14.8 < 0.05
NT > 99th percentile 25.0 5.8 - 82.6 < 0.05
Source: Adapted from Roodpeyma et al27 and Romano-Zelekha et al28 .
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variation of sensitivity among different studies is mainly 
attributable to the following factors:
(1) The cut-off point to separate the normal and 
abnormal NT groups is highly variable – 2.5 mm, 3.5 
mm, 4.0 mm, 95th percentile and 99th percentile, 
depending on the study.
(2) The definition of CHD is not very clear in the 
majority of the studies. Whereas some authors are 
extremely selective and include only the most severe 
diseases that require surgical intervention in the first few 
months of life, others consider even the patent ductus 
arteriosus (which is very common in premature infants) 
as a CHD. 
(3) After the publication of the results obtained by 
Hyett et al25, demonstrating a 56% sensitivity in a study 
with approximately thirty thousand examinations, authors 
with less encouraging results possibly did not publish 
their studies believing that their results were wrong. This 
is called a “publication bias”26.
(4) The primary studies published usually show flaws 
in the statistical planning and little care is taken to review 
the data obtained due to interests and pressures involved
in publications. Thus, primary studies published on any 
subject should be very critically assessed26.
NT value alone should not be used as a single method 
to select the cases that should undergo a thorough 
echocardiography examination. The probability of false 
positives ranged from 86.4% to 97.9%, depending on 
the cut-off point used. The cut-off point producing the 
lower number of false positive was 4.0mm. When this 
cut-off point is used to indicate echocardiography, one 
out of each eight examinations performed is not normal; 
however, 85% of the CHDs are not screened. 
When increased NT and the presence of CHD 
are compared with the classical indications of fetal 
echocardiography, we can observe that an increased NT is 
responsible for a significant increase in the odds ratio for 
CHD. The odds ratio is an alternative form of describing 
the performance of a diagnostic test. It summarizes the 
same type of information provided by the sensitivity and 
specificity, and may be used to calculate the odds of a 
disease after a positive test. 
Thus, if maternal exposure to teratogenic agents and 
a history of a prior child with congenital heart defect are 
indications for fetal echocardiography (odds ratio for CHD 
of 0.9 and 12.4, respectively), so should an increased 
NT be (odds ratios of 4.7 and 25 for the 95th percentile 
and 99th percentile, respectively)27,28.
A screening test should be applied to an apparently 
normal population with the purpose of identifying 
individuals with a high probability of having a certain 
disease. In the majority of cases, a positive screening test 
ultimately leads to a diagnostic test. A good screening 
test should, therefore, have a high sensitivity and a good 
specificity to reduce the number of false positives that 
require further investigation. For a screening test to have 
a clinical significance, once a disease is detected, there 
should be therapeutic choices able to change the outcome 
of the case by reducing mortality and morbidity. 
Training ultrasound specialists to perform a minimum 
screening by assessing the four-chamber and the ouftlow 
tract views has proven to be an efficient methodology. In a 
study conducted by Carvalho et al29,the efficacy of adding 
the outflow tract view to the four chamber view in the 
routine ultrasound examination performed by obstetricians 
was evaluated. The rate of detection of CHD in this study 
was 75%. The authors attributed the successful screening 
rate of the program to an infrastructure dedicated to the 
continued education of the ultrasound specialist team by 
fetal echocardiographists. 
Another promising technology to improve fetal 
cardiac assessment is the STIC (Spatio-temporal image 
correlation). STIC stores three-dimensional blocks of 
the fetal heart, thus reducing the need for examiner’s 
expertise in the assessment of the anatomy of the heart30.
The blocks stored are not restricted to two-dimensional 
images of the region studied, but rather they provide all 
information on the adjacent anatomy. As a consequence, 
the examiner may store a block for further study, obtaining 
different section planes. The blocks may also be sent to 
other experts in fetal echocardiography. 
A study conducted by Gonçalves et al31 verified the 
examiner’s ability to obtain the four chamber plane and the 
outflow tract view from STIC blocks previously acquired. 
Twenty blocks were obtained by one investigator. Further, 
two investigators with notions of fetal echocardiography 
were trained to handle the blocks and obtain the planes 
needed to assess the heart anatomy. The images obtained 
were classified according to their quality. Mean scores 
ranged from acceptable to good for all planes examined 
and no significant differences were observed among 
examiners. Therefore, after larger studies and with the 
reduction of the cost of this technology, STIC will be able 
to help implement a more effective and rapid screening 
method.
We point out the importance of the prenatal detection 
of CHDs, thus bringing a proven benefit for the newborn 
infant. Since NT alone does not seem to be a good 
screening method for CHD, we suggest the implementation 
of other methods, such as training ultrasound specialists 
to obtain and analyze the four-chamber and outflow tract 
views. In the future, technologies such as the STIC should 
be used to improve CHD screening.
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